Suppr超能文献

基于体模的多中心局部进展期宫颈癌定量 MRI 质量保证。

Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer.

机构信息

Department of Radiation Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Danish Centre for Particle Therapy, Aarhus, Denmark.

出版信息

Radiother Oncol. 2020 Dec;153:114-121. doi: 10.1016/j.radonc.2020.09.013. Epub 2020 Sep 12.

Abstract

BACKGROUND AND PURPOSE

A wide variation of MRI systems is a challenge in multicenter imaging biomarker studies as it adds variation in quantitative MRI values. The aim of this study was to design and test a quality assurance (QA) framework based on phantom measurements, for the quantitative MRI protocols of a multicenter imaging biomarker trial of locally advanced cervical cancer.

MATERIALS AND METHODS

Fifteen institutes participated (five 1.5 T and ten 3 T scanners). Each institute optimized protocols for T2, diffusion-weighted imaging, T1, and dynamic contrast-enhanced (DCE-)MRI according to system possibilities, institutional preferences and study-specific constraints. Calibration phantoms with known values were used for validation. Benchmark protocols, similar on all systems, were used to investigate whether differences resulted from variations in institutional protocols or from system variations. Bias, repeatability (%RC), and reproducibility (%RDC) were determined. Ratios were used for T2 and T1 values.

RESULTS

The institutional protocols showed a range in bias of 0.88-0.98 for T2 (median %RC = 1%; %RDC = 12%), -0.007 to 0.029 × 10 mm/s for the apparent diffusion coefficient (median %RC = 3%; %RDC = 18%), and 0.39-1.29 for T1 (median %RC = 1%; %RDC = 33%). For DCE a nonlinear vendor-specific relation was observed between measured and true concentrations with magnitude data, whereas the relation was linear when phase data was used.

CONCLUSION

We designed a QA framework for quantitative MRI protocols and demonstrated for a multicenter trial for cervical cancer that measurement of consistent T2 and apparent diffusion coefficient values is feasible despite protocol differences. For DCE-MRI and T1 mapping with the variable flip angle method, this was more challenging.

摘要

背景与目的

在多中心成像生物标志物研究中,MRI 系统的多样性是一个挑战,因为它会导致定量 MRI 值的变化。本研究旨在设计和测试一个基于体模测量的质量保证(QA)框架,用于局部晚期宫颈癌的多中心成像生物标志物试验的定量 MRI 协议。

材料与方法

15 个研究所参与(5 个 1.5T 和 10 个 3T 扫描仪)。根据系统的可能性、机构的偏好和研究的具体限制,每个研究所都对 T2、扩散加权成像、T1 和动态对比增强(DCE)MRI 协议进行了优化。使用具有已知值的校准体模进行验证。使用类似的基准协议来研究差异是由于机构协议的变化还是由于系统的变化造成的。确定了偏差、重复性(%RC)和再现性(%RDC)。对于 T2 和 T1 值,使用比值。

结果

机构协议显示 T2 的偏差范围为 0.88-0.98(中位数%RC=1%;%RDC=12%),表观扩散系数的偏差为-0.007 至 0.029×10mm/s(中位数%RC=3%;%RDC=18%),T1 的偏差为 0.39-1.29(中位数%RC=1%;%RDC=33%)。对于 DCE,使用幅度数据时,测量值与真实浓度之间存在非线性的供应商特定关系,而使用相位数据时,关系是线性的。

结论

我们为定量 MRI 协议设计了一个 QA 框架,并在宫颈癌的多中心试验中证明,尽管协议存在差异,但仍可以测量一致的 T2 和表观扩散系数值。对于 DCE-MRI 和使用可变翻转角方法的 T1 映射,这更具挑战性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验